论文部分内容阅读
肺癌是危害我国人民健康与生命的重大疾病之一,肺癌的复发和死亡多源于肿瘤转移。上皮细胞的间质化过程(epithelial-mesenchymal transition,EMT)是肺癌转移中的一个关键步骤,此过程涉及E-cadherin表达下调,并受到EMT转录因子调控。组蛋白乙酰转移酶(histone acetyltransferases,HATs)和组蛋白去乙酰化酶(histone deacetyltransferases,HDACs)是催化组蛋白乙酰化和去乙酰化的蛋白家族,不仅在肿瘤进程中发挥重要功能,近年来发现它们同样参与肺癌EMT过程。HATs与HDACs和某些EMT转录因子有相互作用。而且,这些EMT转录因子的功能受乙酰化调控,并影响肺癌EMT进程。本文将分别介绍HATs和HDACs参与肺癌EMT的作用机理,从分子机制方面对它们之间的相互作用进行探讨,并讨论HDAC抑制剂在抑制EMT和肺癌治疗方面的潜在应用价值,以期为相关基础研究和临床实践提供借鉴。
Lung cancer is one of the major diseases endangering the health and life of our people. The recurrence and death of lung cancer are mostly due to tumor metastasis. Epithelial-cell epithelial-mesenchymal transition (EMT) is a key step in the metastasis of lung cancer, involving down-regulation of E-cadherin and regulation of EMT transcription factors. Histone acetyltransferases (HATs) and histone deacetyltransferases (HDACs), a family of proteins that catalyze histone acetylation and deacetylation, not only play an important role in tumor progression, but have been found in recent years They are also involved in the EMT process of lung cancer. HATs interact with HDACs and certain EMT transcription factors. Moreover, the function of these EMT transcription factors is regulated by acetylation and affects lung EMT progression. This article will introduce the mechanism of HATs and HDACs involved in the EMT of lung cancer, explore the molecular mechanisms of their interaction, and discuss the potential application of HDAC inhibitors in the inhibition of EMT and lung cancer treatment, with a view to the relevant basic research And clinical practice to provide reference.